{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:52:41Z","timestamp":1790502761853,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40263-023-01033-4","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T22:01:37Z","timestamp":1694210497000},"page":"819-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Laloyaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-5131","authenticated-orcid":false,"given":"Wendyl","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Soto","family":"Insuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-6627","authenticated-orcid":false,"given":"Jerzy P.","family":"Szaflarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Floricel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Sendersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-5862","authenticated-orcid":false,"given":"Bernhard J.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,9]]},"reference":[{"issue":"2","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/epi.13638","volume":"58","author":"MD Wood","year":"2017","unstructured":"Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2017;58(2):255\u201362.","journal-title":"Epilepsia"},{"issue":"1","key":"1033_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57\u201366.","journal-title":"Epilepsia"},{"issue":"1","key":"1033_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47\u201356.","journal-title":"Epilepsia"},{"issue":"12","key":"1033_CR4","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138.","journal-title":"Epilepsia"},{"issue":"4","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522\u201330.","journal-title":"Epilepsia"},{"issue":"4","key":"1033_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ane.13059","volume":"139","author":"V Villanueva","year":"2019","unstructured":"Villanueva V, L\u00f3pez-Gonz\u00e1lez FJ, Mauri JA, Rodriguez-Uranga J, Oliv\u00e9-Gadea M, Montoya J, et al. BRIVA-LIFE\u2014a multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139(4):360\u20138.","journal-title":"Acta Neurol Scand"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"106657","DOI":"10.1016\/j.yebeh.2019.106657","volume":"102","author":"E Fonseca","year":"2020","unstructured":"Fonseca E, Guzm\u00e1n L, Quintana M, Abraira L, Santamarina E, Salas-Puig X, et al. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav. 2020;102:106657.","journal-title":"Epilepsy Behav"},{"key":"1033_CR8","unstructured":"Bhathal Guede H, Salas-Puig X. BRIVARCAT: Estudio observacional de BRIVaracetam en ARag\u00f3n y CATalu\u00f1a, como terapia a\u00f1adida en epilepsia farmacorresistente. Presented at XXII Reuni\u00f3 Anual de la Societat Catalana de Neurologia, 22\u201323 May 2018, Barcelona, Spain."},{"issue":"7","key":"1033_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/epi.13768","volume":"58","author":"I Steinig","year":"2017","unstructured":"Steinig I, von Podewils F, M\u00f6ddel G, Bauer S, Klein KM, Paule E, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208\u201316.","journal-title":"Epilepsia"},{"issue":"12","key":"1033_CR10","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1111\/epi.17087","volume":"62","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Zaveta C, von Podewils F, M\u00f6ddel G, Langenbruch L, Kovac S, et al. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up. Epilepsia. 2021;62(12):2994\u20133004.","journal-title":"Epilepsia"},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","volume":"48","author":"BJ Steinhoff","year":"2017","unstructured":"Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R, et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy\u2014a monocenter survey. Seizure. 2017;48:11\u20134.","journal-title":"Seizure."},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fneur.2018.00038","volume":"9","author":"F Zahnert","year":"2018","unstructured":"Zahnert F, Krause K, Immisch I, Habermehl L, Gorny I, Chmielewska I, et al. Brivaracetam in the treatment of patients with epilepsy\u2014first clinical experiences. Front Neurol. 2018;9:38.","journal-title":"Front Neurol"},{"key":"1033_CR13","unstructured":"Halliday AJ, Vogrin S, Whitham E, Seneviratne U, Gillinder S, Jones D, et al. Real-world brivaracetam efficacy in adult epilepsy: an Australian multi-centre retrospective observational cohort study. Presented at ANZAN 2022, 10\u201313 May 2022, Melbourne, Australia."},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.yebeh.2020.106967","volume":"106","author":"J Adewusi","year":"2020","unstructured":"Adewusi J, Burness C, Ellawela S, Emsley H, Hughes R, Lawthom C, et al. Brivaracetam efficacy and tolerability in clinical practice: a UK-based retrospective multicenter service evaluation. Epilepsy Behav. 2020;106:106967.","journal-title":"Epilepsy Behav"},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"106757","DOI":"10.1016\/j.eplepsyres.2021.106757","volume":"177","author":"F Ferragut Ferretjans","year":"2021","unstructured":"Ferragut Ferretjans F, Soto Insuga V, Bernardino Cuesta B, Cantar\u00edn Extremera V, Duat Rodriguez A, Legido MJ, et al. Efficacy of brivaracetam in children with epilepsy. Epilepsy Res. 2021;177:106757.","journal-title":"Epilepsy Res"},{"key":"1033_CR16","unstructured":"Daniels T, Soto Insuga V, D'Souza W, Faught E, Klein P, Reuber M, et al. 12-month effectiveness and tolerability of brivaracetam in pediatric patients in the real-world: subgroup data from the EXPERIENCE analysis. Presented at American Epilepsy Society\u201476th, 2\u20136 December 2022, Nashville, TN. Abstract 1.301."},{"key":"1033_CR17","unstructured":"UCB Pharma S.A. Briviact\u00ae (brivaracetam) EU Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf. Accessed 20 Jan 2023."},{"key":"1033_CR18","unstructured":"UCB Pharma. Product Information Briviact. 2017. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-brivaracetam-170307-pi-01.pdf. Accessed 20 Jan 2023."},{"key":"1033_CR19","unstructured":"UCB Inc. Briviact\u00ae (brivaracetam) prescribing information. 2023. https:\/\/www.briviact.com\/briviact-PI.pdf. Accessed 31 Aug 2023."},{"issue":"6","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/clpt.2011.235","volume":"90","author":"S Schneeweiss","year":"2011","unstructured":"Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90(6):777\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1033_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eplepsyres.2016.09.003","volume":"127","author":"BD Moseley","year":"2016","unstructured":"Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmoufti S, Schiemann J, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies. Epilepsy Res. 2016;127:179\u201385.","journal-title":"Epilepsy Res"},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.eplepsyres.2021.106694","volume":"176","author":"BD Moseley","year":"2021","unstructured":"Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: post hoc pooled analysis. Epilepsy Res. 2021;176:106694.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/epi.14476","volume":"59","author":"A Strzelczyk","year":"2018","unstructured":"Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549\u201356.","journal-title":"Epilepsia"},{"issue":"1","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","volume":"70","author":"Y Schiller","year":"2008","unstructured":"Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008;70(1):54\u201365.","journal-title":"Neurology"},{"issue":"5","key":"1033_CR25","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/epi.17223","volume":"63","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Ascoli M, Canafoglia L, Paola Canevini M, Casciato S, Cerulli Irelli E, et al. Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures. Epilepsia. 2022;63(5):e42\u201350.","journal-title":"Epilepsia"},{"issue":"12","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40263-021-00856-3","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, et al. Adjunctive brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35(12):1289\u2013301.","journal-title":"CNS Drugs"},{"issue":"138","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"108967","DOI":"10.1016\/j.yebeh.2022.108967","volume":"23","author":"C Brandt","year":"2023","unstructured":"Brandt C, Dimova S, Elmoufti S, Laloyaux C, Nondonfaz X, Klein P. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: a post hoc analysis of phase 3 trials in adults with focal seizures. Epilepsy Behav. 2023;138:108967.","journal-title":"Epilepsy Behav"},{"key":"1033_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.eplepsyres.2017.02.007","volume":"131","author":"AA Asadi-Pooya","year":"2017","unstructured":"Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, et al. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study. Epilepsy Res. 2017;131:70\u20135.","journal-title":"Epilepsy Res"},{"key":"1033_CR29","doi-asserted-by":"crossref","first-page":"012","DOI":"10.1212\/WNL.0000000000007181","volume":"92","author":"S Chung","year":"2019","unstructured":"Chung S, Martin M, Dimova S, Elmoufti S, Laloyaux C. Long-term retention on adjunctive brivaracetam in adults with focal seizures previously exposed to carbamazepine, lamotrigine, levetiracetam, or topiramate: a post hoc analysis. Neurology. 2019;92:P5.5-012.","journal-title":"Neurology"},{"key":"1033_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D\u2019Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165\u20138.","journal-title":"Epilepsy Behav"},{"key":"1033_CR31","doi-asserted-by":"publisher","first-page":"107939","DOI":"10.1016\/j.yebeh.2021.107939","volume":"118","author":"BJ Steinhoff","year":"2021","unstructured":"Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021;118:107939.","journal-title":"Epilepsy Behav"},{"key":"1033_CR32","doi-asserted-by":"publisher","first-page":"107212","DOI":"10.1016\/j.yebeh.2020.107212","volume":"111","author":"KJ Meador","year":"2020","unstructured":"Meador KJ, Laloyaux C, Elmoufti S, Gasalla T, Fishman J, Martin MS, et al. Time course of drug-related treatment-emergent adverse side effects of brivaracetam. Epilepsy Behav. 2020;111:107212.","journal-title":"Epilepsy Behav"},{"key":"1033_CR33","doi-asserted-by":"crossref","unstructured":"Steinhoff BJ, Christensen J, Doherty CP, Majoie M, Schulz A-L, Brock F, et al. Cognitive performance and retention after 12-month adjunctive brivaracetam in difficult-to-treat patients with epilepsy in a real-life setting. In: 34th International Epilepsy Congress Virtual 28 August\u20131 September 2021; abstract\/poster 96. Epilepsia. 2021;62(S3):3\u2013364.","DOI":"10.1111\/epi.17078"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01033-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01033-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01033-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:21:31Z","timestamp":1694690491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01033-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01033-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"26 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by UCB Pharma. The sponsor was involved in the design of the study, the collection, analysis, and interpretation of data, and in the decision to publish the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"VV has served as a consultant or on an advisory board, for Arvelle Therapeutics, Bial, Eisai, Esteve, GW Pharmaceuticals, Novartis, and UCB Pharma; has received research grants from Bial, Eisai, and UCB Pharma; and has received speaker\u2019s honoraria from Bial, Eisai, Esteve, GW Pharmaceuticals, Novartis, and UCB Pharma. WDS has a salary that is part-funded by The University of Melbourne; he has received travel, investigator-initiated, scientific advisory board, and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel, and speaker honoraria from Eisai Australia & Global; advisory board honoraria from LivaNova and Tilray; educational grants from Novartis, Pfizer, and Sanofi-Synth\u00e9labo; educational, travel, and fellowship grants from GSK Neurology Australia; and honoraria from ScieGen Pharmaceuticals; he has an equity interest in the device company Epiminder. EF has received research grants from Janssen and UCB Pharma, and has served as a consultant for Aucta, Biogen, Eisai, LivaNova, Neurelis, SK Life Science, and Trevena. PK has served as a consultant for Abbott, Arvelle Therapeutics, Neurelis, and SK Life Science; as a consultant, advisory board member, and speaker for Aquestive, Eisai, Sunovion, and UCB Pharma; is a member of the medical advisory board of Stratus and the scientific advisory board of OB Pharma; is the CEO of PrevEp; and has received research support from CURE and Department of Defense\/Lundbeck. MR receives payment from Elsevier as editor-in-chief of <i>Seizure<\/i>; and has received research grants and speaker\u2019s fees from Eisai, LivaNova, and UCB\u00a0Pharma. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals; personal fees and other from Novartis; personal fees and grants from UCB Pharma; and grants from the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt, Deutsche Forschungsgemeinschaft, the European Union, and the State of Hessen outside of the submitted work. JSP has received grants from Bial and UCB Pharma; and reports personal fees from Bial, Eisai, Esteve, Sanofi, and UCB Pharma outside of the submitted work. VSI has received speaker honoraria from Bial, Eisai, and UCB Pharma. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW\/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma\/Zogenix, and UNEEG Medical, outside of the submitted work. JPS has received research funding from Biogen, Department of Defense, Eisai, GW Pharmaceuticals companies, National Institutes of Health, National Science Foundation, NeuroPace, Serina Therapeutics, Shor Foundation for Epilepsy Research, State of Alabama General Funds, and UCB Pharma; has served as a consultant or advisory board member for Elite Medical Experts, GW Pharmaceuticals companies, LivaNova, Lundbeck, Medical Association of the State of Alabama, NeuroPace, Serina Therapeutics, SK Life Science, and UCB Pharma; has served as an investigator on GW Research Ltd trials; and is an editorial board member for <i>Epilepsy & Behavior, Epilepsy & Behavior Reports<\/i> (editor-in-chief), <i>Folia Medica Copernicana, Journal of Epileptology<\/i> (associate editor), and <i>Journal of Medical Science<\/i>. HB, CC, TD, FF, CL, and VS are employees of UCB Pharma. DF is an independent contractor working for UCB Pharma. BJS has received speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, and UCB Pharma; and has served as a consultant for Arvelle Therapeutics, B. Braun, Bial, Desitin, Eisai, GW Pharmaceuticals, and UCB Pharma. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data from non-interventional studies are outside of UCB Pharma\u2019s data sharing policy and are unavailable for sharing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No ethics committee approval was required for the EXPERIENCE database given that the database consisted of Health Insurance Portability and Accountability Act and General Data Protection Regulation (GDPR) compliant anonymised data. The Australian (AUS) and United States of America (USA) cohorts required ethics approval to release their data for inclusion in the EXPERIENCE database. Each non-interventional study that was included in EXPERIENCE received appropriate ethics and\/or scientific review board approval as part of the initial study proposal at each institution.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to study conception\/design, or acquisition\/analysis\/interpretation of data; and drafting of the manuscript, or revising it critically for important intellectual content. All authors read and provided final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}